Crossing the next frontier to give you a fair chance to fight
Exeliom Biosciences is a clinical-stage biotechnology company leading the development of EXL01, a first-in-class immunomodulator designed to target NOD2 receptors in macrophages.
By uniquely activating the NOD2 pathway, EXL01 drives metabolic reprogramming in monocytes and macrophages, unlocking powerful and precise immune-modulatory effects. Harnessing the versatility of this groundbreaking mechanism, EXL01 is currently in Phase 2 clinical trials across multiple therapeutic areas, including oncology (gastric, NSCLC, HCC, RCC), inflammatory bowel diseases (Crohn's disease), and infectious diseases (C. difficile infections).
At Exeliom, we are transforming scientific innovation into transformative therapies.
NOD2: Unlocking Transformative Potential Across Key Disease Areas
NOD2 is a groundbreaking and versatile therapeutic target, acting as a critical intracellular receptor responsible for detecting bacterial components like peptidoglycans.
By modulating monocytes and macrophages, NOD2 orchestrates essential immune responses, bridging inflammation, infection control, and tissue repair.
Dysregulation or mutations in NOD2 have been linked to a range of inflammatory diseases, metabolic disorders, and cancers, highlighting its central role in disease pathology.
As a master regulator of immune modulation, NOD2 offers untapped therapeutic potential to transform treatment landscapes across diverse medical areas.
NOD2: A Dual Regulator of Macrophage Polarization and Immune Responses
NOD2 plays a pivotal role in innate immunity by recognizing MDP, a fragment of bacterial peptidoglycan.
Through its regulation of key metabolic pathways, such as the shift between oxidative phosphorylation and glycolysis, NOD2 influences macrophage behavior based on contextual factors, including circulating T-cell levels, cytokines like TNF-α and IFN-γ, gut localization, and NOD2 expression levels. It acts as a reciprocal modulator, governing the activation and polarization of macrophages between the pro-inflammatory M1 and anti-inflammatory M2 phenotypes.
EXL01 harnesses its unique NOD2 agonist properties to deliver precise and targeted immune modulation.
It plays a dual role in regulating macrophages activation and polarization between M1 and M2 phenotypes.
EXL01: A Breakthrough in Microbiome-Based Immunomodulation
EXL01 is a first-in-class immunomodulator and single-strain Live Biotherapeutic Product derived from Faecalibacterium prausnitzii, a key player in the gut microbiome.
Leveraging the distinct peptidoglycan structure of F. prausnitzii, EXL01 hyperactivates the NOD2 pathway to drive metabolic reprogramming in monocytes and macrophages, resulting in superior immune-modulatory effects.
Designed for oral, daily administration, EXL01 is a gastro-resistant drug engineered to release precisely in the jejunum and ileum, ensuring targeted immune activation without requiring gut colonization. Currently in Phase 2 clinical trials across oncology, inflammatory bowel diseases and infectious diseases, EXL01 has shown a robust safety profile in Phase 1 studies and is supported by scalable manufacturing capabilities.
With its innovative mechanism, proprietary NOD2 agonist properties and strong scientific foundation, EXL01 is positioned to address significant unmet medical needs and redefine the potential of microbiome-based therapies.
Exeliom is based on strong scientific foundations and has a world-renowned team, led by Pr. Harry Sokol, gastroenterologist and hepatologist at Saint-Antoine Hospital,AP-HP and Sorbonne University, Dr. Philippe Langella, research director at INRAE, and Pr. Patrick Gervais, process engineering specialist at AgroSup.
Founded in 2016 and headquartered in Paris, Exeliom has raised a total of €24 million ($26M) since its inception.
The company has been awarded the ‘Deeptech’ and ‘I-Lab’ awards by Bpifrance, and the ‘EIC Accelerator’ by the European Innovation Council Fund. It has also received financial support from the Crohn's & Colitis Foundation of America.
Giving patients a fair chance to fight is why we seek out unexplored therapeutic solutions, and why we founded Exeliom Biosciences.
